Related Experiment Videos
Bisphosphonates and metastatic breast carcinoma
1Division of Hematology/Oncology, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA. Alipton@psu.edu
Cancer
|January 28, 2003
Summary
Zoledronic acid effectively prevents skeletal complications in advanced breast cancer patients, matching pamidronate efficacy. This bisphosphonate treatment delays bone events, improving patient quality of life.
Area of Science:
- Oncology
- Pharmacology
- Skeletal Metastasis Research
Background:
- Skeletal metastasis affects ~75% of advanced breast cancer patients, causing significant morbidity.
- Bone metastases lead to decreased quality of life in patients with advanced breast cancer.
Purpose of the Study:
- To compare the efficacy of zoledronic acid versus pamidronate in managing skeletal complications in metastatic breast cancer.
- To evaluate zoledronic acid as a treatment for osteolytic and osteoblastic bone metastases.
Main Methods:
- A Phase 3 clinical trial was conducted comparing zoledronic acid (4 mg and 8 mg) with pamidronate (90 mg).
- Treatment was administered every 3-4 weeks via a 15-minute infusion.
Main Results:
- Zoledronic acid 4 mg infusion was found to be at least as effective as pamidronate 90 mg.
- The study demonstrated efficacy in preventing skeletal complications in patients with metastatic breast cancer.
Conclusions:
- Bisphosphonate therapy, including zoledronic acid, can delay skeletal events in patients with bone metastases from breast cancer.
- Results support further investigation and clinical application of bisphosphonates in managing skeletal-related events.